Page 102 - 《中国药房》2024年10期
P. 102

model  for  screening  acute  ischemic  stroke  patients  with   organized  management[J].  Chin  J  Stroke,2023,18(7):
               more than 10 cerebral microbleeds[J]. Front Neurol,2022,  822-828.
               13:833952.                                     [17]  董漪,徐嘉文,董强. 替奈普酶的溶栓“新时代”[J]. 现代
          [ 7 ]  段蓉,李正翔. 国内外药物警戒研究现状与热点的文献                         实用医学,2023,35(8):981-983.
               计量学分析[J]. 中国药房,2022,33(1):116-122.                  DONG Y,XU J W,DONG Q. Thrombolytic “new era” of
               DUAN R,LI Z X. Bibliometric analysis of status quo and   teneplase[J]. Mod Pract Med,2023,35(8):981-983.
               hot  spots  of  domestic  and  foreign  pharmacovigilance       [18]  PARSONS  M,SPRATT  N,BIVARD  A,et  al.  A  ran-
               research[J]. China Pharm,2022,33(1):116-122.        domized  trial  of  tenecteplase  versus  alteplase  for  acute
          [ 8 ]  WAHLGREN N,AHMED N,DÁVALOS A,et al. Throm‐        ischemic stroke[J]. N Engl J Med,2012,366(12):1099-
               bolysis with alteplase 3-4.5 h after acute ischaemic stroke  1107.
              (SITS-ISTR):an  observational  study[J].  Lancet,2008,  [19]  TSIVGOULIS G,KATSANOS A H,CHRISTOGIANNIS
               372(9646):1303-1309.                                C,et  al.  Intravenous  thrombolysis  with  tenecteplase  for
          [ 9 ]  KVISTAD  C  E,NÆSS  H,HELLEBERG  B  H,et  al.        the  treatment  of  acute  ischemic  stroke[J].  Ann  Neurol,
               Tenecteplase versus alteplase for the management of acute   2022,92(3):349-357.
               ischaemic  stroke  in  Norway(NOR-TEST  2,part  a):a   [20]  FERGUSON E,YADAV K. Intravenous tenecteplase com‐
               phase  3,randomised,open-label,blinded  endpoint,       pared with alteplase for acute ischemic stroke in Canada
               non-inferiority  trial[J].  Lancet  Neurol,2022,21(6):  (AcT):a  pragmatic,multicentre,open-label,registry-
               511-519.                                            linked,randomised,controlled,non-inferiority  trial[J].
          [10]  YAGHI  S,WILLEY  J  Z,CUCCHIARA  B,et  al.  Treat‐  CJEM,2023,25(2):121-122.
               ment  and  outcome  of  hemorrhagic  transformation  after     [21]  WANG Y J,LI S Y,PAN Y S,et al. Tenecteplase versus
               intravenous alteplase in acute ischemic stroke:a scientific   alteplase  in  acute  ischaemic  cerebrovascular  events
               statement for healthcare professionals from the American   (TRACE-2):a  phase  3,multicentre,open-label,ran‐
               Heart Association/American Stroke Association[J]. Stroke,  domised controlled,non-inferiority trial[J]. Lancet,2023,
               2017,48(12):e343-e361.                              401(10377):645-654.
          [11]  YANG C J,HAWKINS K E,DORÉ S,et al. Neuroinflam‐  [22]  中国医师协会神经内科医师分会脑血管病专家组. 急性
               matory  mechanisms  of  blood-brain  barrier  damage  in    缺血性卒中替奈普酶静脉溶栓治疗中国专家共识[J]. 中
               ischemic stroke[J]. Am J Physiol Cell Physiol,2019,316  国神经精神疾病杂志,2022,48(11):641-651.
              (2):C135-C153.                                       Cerebrovascular  Disease  Group  of  Neurology  Sub-
          [12]  HUANG  P,YI  X Y.  Predictive  role  of  admission  serum      Association  of  Chinese  Medical  Doctor  Association.
               glucose,baseline NIHSS score,and fibrinogen on hemor‐  Chinese expert consensus on teneplase intravenous throm‐
               rhagic transformation after intravenous thrombolysis with   bolytic therapy for acute ischemic stroke[J]. Chin J Nerv
               alteplase in acute ischemic stroke[J]. Eur Rev Med Phar‐  Ment Dis,2022,48(11):641-651.
               macol Sci,2023,27(20):9710-9720.               [23]  POP R,FINITSIS S N,ARQUIZAN C,et al. Poor clinical
          [13]  FINNSDÓTTIR  H,SZEGEDI  I,OLÁH  L,et  al.  The        outcome  despite  successful  basilar  occlusion  recanali-
               applications of transcranial doppler in ischemic stroke[J].   zation in the early time window:incidence and predictors
               Ideggyogy Sz,2020,73(11/12):367-378.                [J]. J Neurointerv Surg,2023,15(5):415-421.
          [14]  FERRARA A. Computed tomography in stroke diagnosis,  [24]  FLOCH  A  L,CLARENÇON  F,ROUCHAUD  A,et  al.
               assessment,and  treatment[J].  Radiol  Technol,2020,91  Influence  of  prior  intravenous  thrombolysis  in  patients
              (5):447CT-462CT.                                     treated with mechanical thrombectomy for M2 occlusions:
          [15]  ZHONG C S,BEHARRY J,SALAZAR D,et al. Routine       insight from the endovascular treatment in ischemic stroke
               use  of  tenecteplase  for  thrombolysis  in  acute  ischemic   (ETIS)registry[J].  J  Neurointerv  Surg,2023,15(e2):
               stroke[J]. Stroke,2021,52(3):1087-1090.             e289-e297.
          [16]  楼敏,丁晶,张玉生,等. 中国脑血管病临床管理指南:第                   [25]  XIONG Y Y,YAN R,GU H Q,et al. Intravenous throm‐
               2版:节选:第2章 卒中组织化管理推荐意见[J]. 中国卒                       bolysis in Chinese patients with mild acute ischemic stroke
               中杂志,2023,18(7):822-828.                             [J]. Ann Transl Med,2021,9(9):767.
               LOU M,DING J,ZHANG Y S,et al. Chinese stroke asso‐           (收稿日期:2023-12-13  修回日期:2024-04-28)
               ciation guidelines for clinical management of cerebrovas‐                          (编辑:陈 宏)
               cular diseases:second edition:excerpt:chapter two stroke







          · 1248 ·    China Pharmacy  2024 Vol. 35  No. 10                            中国药房  2024年第35卷第10期
   97   98   99   100   101   102   103   104   105   106   107